Contextualizing the Modern Epidemiology of Neurofibromatosis Type 2 in an Era of Heightened Detection of Sporadic Vestibular Schwannoma

被引:2
|
作者
Dowling, Eric M. [1 ]
Marinelli, John P. [2 ]
Lohse, Christine M. [3 ]
Carlson, Matthew L. [1 ,4 ]
机构
[1] Mayo Clin, Dept Otolaryngol Head & Neck Surg, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Alix Sch Med, Rochester, MN USA
[3] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN USA
[4] Mayo Clin, Dept Neurol Surg, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
Acoustic neuroma; Epidemiology; Incidence; Neurofibromatosis type 2; Prevalence; Rochester epidemiology project; Schwannomatosis; Vestibular schwannoma; MEDICAL-RECORDS LINKAGE; TUMOR-PRONE SYNDROMES; SOMATIC MOSAICISM; ACOUSTIC NEUROMA; POPULATION; PREVALENCE; FREQUENCY; DISEASE; RISK; GENE;
D O I
10.1097/MAO.0000000000002557
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective:Closely paralleling previous radiologic studies, recent population-based prevalence data suggest sporadic vestibular schwannoma (VS) affects over one in 2,000 adults and up to one in 500 in those aged 70 years or older. Attributable to increased utilization of magnetic resonance imaging and screening protocols for asymmetrical sensorineural hearing loss, the increasing detection rate of sporadic VS fundamentally changes the perception of VS as a whole. The primary objective of the current study was to contextualize modern epidemiological trends in neurofibromatosis type 2 (NF2) in light of these recent advancements in the understanding of sporadic VS.Study Design:Population-based study.Setting:Olmsted County, Minnesota. Population size on January 1, 2017: 159,689 people.Patients:All patients with NF2 diagnosed between Jan 1, 1966 and Dec 31, 2016, identified using the Rochester Epidemiology Project.Main Outcome Measures:Incidence, prevalence.Results:Six incident cases were identified over the past 50 years. From 1966 to 2016, the age- and sex-adjusted incidence rate was 0.10 per 100,000 person-years. The incidence rate remained at 0.12 over the most recent decade. Five cases met disease prevalence criteria, and the age- and sex-adjusted prevalence of NF2 on Jan 1, 2017 was 3.1 per 100,000 persons. All prevalent cases were women, and the resultant prevalence among women only was 6.0 per 100,000 persons.Conclusions:The modern age- and sex-adjusted incidence rate and prevalence of NF2 is 0.10 per 100,000 person-years and 3.1 per 100,000 persons, respectively. In contrast to trends in incidence rates of sporadic VS over the last half-century, this study demonstrates that the incidence of NF2 has remained relatively stable since 1966. This divergence in epidemiological trends is likely attributed to the nature of NF2, with early clinical manifestations resulting in diagnosis regardless of modern advances, whereas the increased incidence of sporadic VS is heavily influenced by improved detection in a greater population of patients with minimally symptomatic or asymptomatic tumors.
引用
收藏
页码:E501 / E506
页数:6
相关论文
共 50 条
  • [21] Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2
    Eiji Ito
    Kiyoshi Saito
    Hiroshi Yatsuya
    Tetsuya Nagatani
    Goro Otsuka
    Neurosurgical Review, 2009, 32 : 425 - 433
  • [22] Long-Term Effects of Bevacizumab on Vestibular Schwannoma Volume in Neurofibromatosis Type 2 Patients
    Killeen, Daniel E.
    Klesse, Laura
    Tolisano, Anthony M.
    Hunter, Jacob B.
    Kutz, Joe Walter, Jr.
    JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE, 2019, 80 (05) : 540 - 545
  • [23] Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study
    Mautner, VF
    Baser, ME
    Thakkar, SD
    Feigen, UM
    Friedman, JM
    Kluwe, L
    JOURNAL OF NEUROSURGERY, 2002, 96 (02) : 223 - 228
  • [24] Neurofibromatosis type 2 versus sporadic vestibular schwannoma: The utility of MR diffusion and dynamic contrast-enhanced imaging
    Ota, Yoshiaki
    Liao, Eric
    Capizzano, Aristides A.
    Baba, Akira
    Kurokawa, Ryo
    Kurokawa, Mariko
    Srinivasan, Ashok
    JOURNAL OF NEUROIMAGING, 2022, 32 (03) : 554 - 560
  • [25] Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
    Plotkin, Scott R.
    Halpin, Chris
    Blakeley, Jaishri O.
    Slattery, William H., III
    Welling, D. Bradley
    Chang, Susan M.
    Loeffler, Jay S.
    Harris, Gordon J.
    Sorensen, A. Gregory
    McKenna, Michael J.
    Barker, Fred G., II
    JOURNAL OF NEURO-ONCOLOGY, 2009, 93 (01) : 61 - 77
  • [26] Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
    Scott R. Plotkin
    Chris Halpin
    Jaishri O. Blakeley
    William H. Slattery
    D. Bradley Welling
    Susan M. Chang
    Jay S. Loeffler
    Gordon J. Harris
    A. Gregory Sorensen
    Michael J. McKenna
    Fred G. Barker
    Journal of Neuro-Oncology, 2009, 93 : 61 - 77
  • [27] Endoglin (CD105) expression in neurofibromatosis type 2 vestibular schwannoma
    Marioni, Gino
    Nicole, Lorenzo
    Cazzador, Diego
    Pavone, Chiara
    D'Avella, Domenico
    Martini, Alessandro
    Mazzoni, Antonio
    Zanoletti, Elisabetta
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (10): : 3612 - 3617
  • [28] Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2
    Li, Huan
    Hao, Shu-Yu
    Wang, Liang
    Li, Da
    Wu, Zhen
    Zhang, Li-Wei
    Zhang, Jun-Ting
    ACTA NEUROCHIRURGICA, 2015, 157 (11) : 1983 - 1990
  • [29] Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2
    Huan Li
    Shu-Yu Hao
    Liang Wang
    Da Li
    Zhen Wu
    Li-Wei Zhang
    Jun-Ting Zhang
    Acta Neurochirurgica, 2015, 157 : 1983 - 1990
  • [30] Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients
    Fujii, Masazumi
    Ichikawa, Masahiro
    Iwatate, Kensho
    Bakhit, Mudathir
    Yamada, Masayuki
    Kuromi, Yosuke
    Sato, Taku
    Sakuma, Jun
    Saito, Kiyoshi
    NEUROLOGIA MEDICO-CHIRURGICA, 2020, 60 (02) : 75 - 82